Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis.
Bernardete PessoaLuísa MalheiroInês CarneiroSílvia MonteiroJoão CoelhoConstanca CoelhoJoão FigueiraAngelina MeirelesJoão Nuno Melo BeirãoPublished in: Clinical ophthalmology (Auckland, N.Z.) (2021)
In persistent DME unresponsive to bevacizumab, both anatomical and functional improvements were observed with ranibizumab whereas aflibercept only showed an anatomical improvement. Clinicaltrials.gov NCT04018833.